相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).
Matthew T Campbell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia
Kerry L. Reynolds et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
Douglas B Johnson et al.
LANCET ONCOLOGY (2020)
Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Susan Spillane et al.
ONCOLOGIST (2020)
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
Emanuel Raschi et al.
TARGETED ONCOLOGY (2020)
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
Ying Jing et al.
NATURE COMMUNICATIONS (2020)
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
Huan-huan Ji et al.
CLINICAL DRUG INVESTIGATION (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review
Meghan E. Sise et al.
ONCOLOGIST (2019)
Immune-related adverse events for different age groups using the FDA Adverse Event Reporting System.
Zin Myint et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Douglas B. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
Harish Seethapathy et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
Yinghong Zhai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
Houssein Safa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO plus IPI: a systematic review and meta-analysis
Puyuan Xing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass
Ann V. Schwartz et al.
DIABETES (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Tomas G. Neilan et al.
ONCOLOGIST (2018)
Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A US Food and Drug Administration pooled analysis.
Laleh Amiri-Kordestani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
Daniel Y. Wang et al.
ONCOIMMUNOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
分享论文
